WRAL Tech Wire

 Durham drug firm Chimerix reports $9.1M quarterly loss

The company, which went public in April, reports a drop in revenue and an increase in expenses. But stock rallies 4 percent on the news.

 Chimerix hires drug development chief; SciQuest names new marketing and product development execs

 Chemistry among people, companies is crucial to biochemistry deals

Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.

Drug deal

 RTP drug firm Chimerix names former GSK exec as chief medical officer

Dr. Michelle Berrey, MD, joins the firm from Pharmasset where she also served as CMO. Pharmasset was acquired by Gilead Sciences earlier this year.

 Merck licenses HIV compound from RTP-based Chimerix

In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.

 Startup Chimerix reports positive test news for transplant drug

The company is studying the compound for the prevention of cytomegalovirus diseases, or CMV, in patients who have had stem cell transplants.

 Durham biotech firm wins round in $2B contract battle

Chimerix fought the award of a sole-source contract for a potential smallpox treatment to another firm and convinces the government agency involved to overturn it. Now, Chimerix can compete for a lucrative deal, CEO says.

 Chimerix lands $24.8 million contract for smallpox drug

Under the terms of this BARDA contract, Chimerix potentially could net almost $81.1 million total.

 Chimerix secures $45M round for antiviral medicines

New funding is aimed at further development of vitally important new antiviral medicines for the treatment of life-threatening diseases.

 Chimerix expands leadership with business development post

The biotechnology firm recently reshuffled its management team, board.

 RTP biotech firm Chimerix names new CEO, shuffles board

The company, which is developing antiviral treatments that can be taken orally, promotes its chief operating officer to top post. Its former CEO is now chief science officer.